Journal
STEM CELL REPORTS
Volume 3, Issue 1, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.stemcr.2014.04.020
Keywords
-
Categories
Funding
- NCRR, NIH [P40RR017447]
- Connecticut Stem Cell Research [12-SCD-UCHC-01, 13-SCD-UCHC-01, 13-SCDIS-ISB-01, 10SCA21]
- ImStem Biotechnology and Advanced Cell Technology
Ask authors/readers for more resources
Current therapies for multiple sclerosis (MS) are largely palliative, not curative. Mesenchymal stem cells (MSCs) harbor regenerative and immunosuppressive functions, indicating a potential therapy for MS, yet the variability and low potency of MSCs from adult sources hinder their therapeutic potential. MSCs derived from human embryonic stem cells (hES-MSCs) may be better suited for clinical treatment of MS because of their unlimited and stable supply. Here, we show that hES-MSCs significantly reduce clinical symptoms and prevent neuronal demyelination in a mouse experimental autoimmune encephalitis (EAE) model of MS, and that the EAE disease-modifying effect of hES-MSCs is significantly greater than that of human bone-marrow-derived MSCs (BM-MSCs). Our evidence also suggests that increased IL-6 expression by BM-MSCs contributes to the reduced anti-EAE therapeutic activity of these cells. A distinct ability to extravasate and migrate into inflamed CNS tissues may also be associated with the robust therapeutic effects of hES-MSCs on EAE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available